Update: Independently Owned Pharmacy Closures in Rural America, 2003-2018
Provides updated information on independently owned rural pharmacy closures from 2003 to 2018. Includes state-level data on rural pharmacy closures. Builds on past publications from RUPRI regarding rural pharmacy closures.
Author(s): Abiodun Salako, Fred Ullrich, Keith J. Mueller
Date: 07/2018
Type: Document
Sponsoring organization: RUPRI Center for Rural Health Policy Analysis
view details

Drug Discount Program: Characteristics of Hospitals Participating and Not Participating in the 340B Program
Analyzes 2016 cost report data to describe and compare characteristics of 340B participating and non-participating hospitals, specifically examining three hospital types: Critical Access Hospitals (CAHs), Sole Community Hospitals (SCHs), and general acute care hospitals. Discusses trends related to decreased charity care and an increase in Medicaid expansion on 340B hospital participation.
Additional links: Full Report
Date: 07/2018
Type: Document
Sponsoring organization: Government Accountability Office
view details

Drug Discount Program: Improvements Needed in Federal Oversight of Compliance at 340B Contract Pharmacies
Details an evaluation of HRSA's oversight of contract pharmacies participating in the 340B Drug Pricing Program. Discusses rates of compliance by contract pharmacies and HRSA's enforcement efforts.
Additional links: Full Report
Date: 07/2018
Type: Document
Sponsoring organization: Government Accountability Office
view details

Drug Discount Program: Federal Oversight of Compliance at 340B Contract Pharmacies Needs Improvement
Focuses on the 340B Drug Pricing Program, which allows certain facilities such as Disproportionate Share Hospitals (DSHs), Federally Qualified Health Centers (FQHCs), and Critical Access Hospitals (CAHs) to purchase prescription and non-prescription medications at reduced cost. Describes financial arrangements participating facilities have with contract pharmacies, the extent to which they provide discounts on 340B drugs dispensed by contract pharmacies to low-income, uninsured patients, and examines the Health Resources and Services Administration's efforts to ensure compliance with 340B Program requirements at contract pharmacies.
Additional links: Full Report
Date: 06/2018
Type: Document
Sponsoring organization: Government Accountability Office
view details

The Special Registration for Telemedicine: In Brief
Describes a proposed policy, as a means to address the opioid crisis, requiring providers who use telemedicine to complete a special registration process to increase access to telemedicine services, including the remote prescribing of medicine for substance abuse or mental health treatment. Covers special registration requirements and the seven categories under the practice of telemedicine authority recognized by the Controlled Substance Act (CSA).
Date: 06/2018
Type: Document
Sponsoring organization: Congressional Research Service
view details

Report to Congress on Medicaid and CHIP, June 2018
Provides an in-depth examination of and makes recommendations on two critical issues, the high cost of prescription drugs and the opioid epidemic, as they relate to Medicaid. The opioid section includes discussion of rural access to treatment for substance use disorder. Also discusses Medicaid’s role as the nation’s largest payer for long-term services and supports.
Date: 06/2018
Type: Document
Sponsoring organization: Medicaid and CHIP Payment and Access Commission
view details

SAMHSA Opioid Overdose Prevention Toolkit
Provides strategies for healthcare providers, communities, and local governments to help prevent opioid-related overdoses and deaths. Includes facts for community members, essential steps for first responders, information for prescribers, safety advice for patients and family members, and resources for overdose survivors and their families.
Date: 06/2018
Type: Document
Sponsoring organization: Substance Abuse and Mental Health Services Administration
view details

Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine
Highlights a study on the prescribing practices of rural physicians with buprenorphine waivers, which allow them to provide medication-assisted treatment (MAT) for opioid used disorder. Findings are based on surveys of all rural physicians with a Drug Enforcement Administration prescription waiver. Breaks down data by physician specialty, practice type, and waiver type, among other factors.
Author(s): Holly A. Andrilla, Cynthia Coulthard, Davis G. Patterson
Citation: American Journal of Preventive Medicine, 54(6) S3, S208-S214
Date: 06/2018
Type: Document
view details

Drug Discount Program: Status of Agency Efforts to Improve 340B Program Oversight
Testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate, describing the Health Resources and Services Administration's (HRSA) actions in response to the Government Accountability Office's (GAO) recommendations to improve the 340B program oversight. Covers GAO's ongoing work related to the 340B program and HRSA's efforts to implement the GAO's recommendations. includes information on 340B program participants, program structure, operation, and key requirements.
Additional links: Examining Oversight Reports on the 340B Drug Pricing Program, Full Report
Date: 05/2018
Type: Document
Sponsoring organization: Government Accountability Office
view details

The “M” of MAT: Medications for Opioid Use Disorder
A brief overview of medications used to treat opioid use disorder, as part of whole-patient treatment which includes counseling and behavioral therapies.
Author(s): Kay Miller Temple
Citation: Rural Monitor
Date: 03/2018
Type: Document
Sponsoring organization: Rural Health Information Hub
view details